Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9348378 | 0.85 | NAMPT (0.44) | USP2LMNACYP2C9CYP2C19TSHR | |
| SCHEMBL23288368 | 0.84 | LMNA (0.60) | LMNATSHRHSD17B10HDAC3HDAC1 | |
| SCHEMBL2056117 | 0.83 | HDAC3 (0.49) | LMNACYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL8286119 | 0.83 | HDAC3 (0.49) | LMNATSHRMEN1KMT2AMAPT | |
| SCHEMBL1956844 | 0.83 | HDAC3 (0.52) | LMNATSHRMEN1KMT2AMAPT | |
| SCHEMBL30400038 | 0.83 | CYP17A1 (0.46) | USP2TSHRHSD17B10HDAC3HDAC1 | |
| SCHEMBL2056134 | 0.82 | HDAC3 (0.49) | LMNACYP2C9MEN1KMT2ACYP3A4 | |
| SCHEMBL14587226 | 0.82 | HDAC3 (0.51) | LMNAMEN1KMT2AMAPTHDAC3 | |
| SCHEMBL23545662 | 0.82 | HDAC1 (0.48) | LMNATSHRMEN1KMT2AHSD17B10 | |
| SCHEMBL3156567 | 0.82 | HDAC1 (0.48) | LMNATSHRMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314217-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20110224130-A1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | THERAVANCE, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7871997-B2 | Cephalosporin compounds | THERAVANCE, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| EP-1633759-B1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | THERAVANCE INC (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080103299-A1 | Cross-linked glycopeptide - cephalosporin antibiotics | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2008-05-01 | — | — | US | disclosed |
| US-7332471-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7067481-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-20060128612-A1 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2006-06-15 | — | — | US | disclosed |
| EP-1633759-A1 | CROSS-LINKED GLYCOPEPTIDE - CEPHALOSPORIN ANTIBIOTICS | Theravance, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20040266666-A1 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2004-12-30 | — | — | US | disclosed |
| EP-0723545-B1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LAB (US) | 2002-05-08 | — | — | EP | disclosed |
| CN-1053188-C | Quinolizinone type compounds | ABBOTT LAB (US) | 2000-06-07 | — | — | CN | disclosed |
| EP-0871628-A1 | QUINOLIZINONE TYPE COMPOUNDS | Abbott Laboratories (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5726182-A | TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1998-03-10 | — | — | US | disclosed |
| US-5599816-A | BACTERICIDE | ABBOTT LABORATORIES (US) | 1997-02-04 | — | — | US | disclosed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
| CN-1137273-A | Quinolizinone type compounds | ABBOTT LAB (US) | 1996-12-04 | — | — | CN | disclosed |
| US-5580872-A | ADMINISTERING IN THE TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1996-12-03 | — | — | US | disclosed |
| EP-0723545-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1995010519-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1995-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266666-A1 | Cross-linked glycopeptide-cephalosporin antibiotics | GYPA, CSGALNACT1, ST3GAL3 | USP2 2674/4885LMNA 3170/4885CYP2C9 1062/4885 |
| US-20060128612-A1 | Cross-linked glycopeptide-cephalosporin antibiotics | CSGALNACT1, GYPA, ST3GAL3 | USP2 2726/4885LMNA 3243/4885CYP2C9 1234/4885 |
| US-20080103299-A1 | Cross-linked glycopeptide - cephalosporin antibiotics | CSGALNACT1, GYPA, ST3GAL3 | USP2 2799/4885LMNA 3192/4885CYP2C9 1300/4885 |
| US-20110224130-A1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | CSGALNACT1, GYPA, ST3GAL3 | USP2 2799/4885LMNA 3192/4885CYP2C9 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.